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431 AUGMENTATION OF ANTI-INFLAMMATORY EFFECTS OF
DEXAMETHASONE BY SUPPRESSING ABCB1 GENE
EXPRESSION
K. Honjo, K.A. Takahashi, O. Mazda, T. Kishida, N. Hiraoka, A. Inoue,
M. Saito, H. Inoue, J. Imanishi, T. Kubo. Kyoto Prefectural University of
Medicine, Kyoto, JAPAN
Purpose: To investigate whether ATP-binding cassette sub-family B
member1 (ABCB1) gene silencing in ﬁbroblast-like synoviocytes (FLSs)
by RNA interference enhances anti-inﬂammatory effects of dexametha-
sone (DEX) in vitro.
Methods: CIA was induced in Dark Agouti rats (8−10 weeks of age) by an
intradermal injection of an emulsion of bovine typeII collagen in Freund’s
adjuvant at the base of the tail. FLSs were isolated from synovium of
rat knee joints 14 days after immunization. FLSs were cultured with
various concentration of DEX (0–100 nM) for 4 hr in DMEM medium
with 1% fetal calf serum. In some experiments, in order to investigate
whether changes in ABCB1b gene expression affect the anti-inﬂammatory
performance of DEX, the cells were also transfected with 100 nM of small
interfering RNA (siRNA) targeted to ABCB1b (siABCB1b) 48 hr before
DEX treatment. Total RNAs were extracted from the cells, and mRNA
levels of ABCB1a/1b and Il-6 were determined using quantitative real-
time PCR.
Results: ABCB1b mRNA levels were approximately 4 fold of ABCB1a
in cultured FLS without any treatment (Fig 1), and then, siABCB1b
was used in the following experiments. With transfection of synthetic
siABCB1b, ABCB1b mRNA levels was reduced approximately 70% of that
in control cells (Fig 2). After treatment with DEX at concentration of 1, 10,
100 nM to FLS, the expression of Il-6 mRNA were inhibited to 81.0±24,
34.8±14, 22.1±3.2 (%), respectively, compared to control cells (Fig 3).
When transfection with siABCB1b was performed in combination with
DEX treatment (1, 10, 100 nM), Il-6 expression was markedly reduced to
51.7±5.0, 16.2±2.3, 14.8±2.7 (%), respectively (Fig 3).
Conclusions: ABCB1 gene encodes P-glycoprotein (P-gp), a pump
molecule which is a 170 kDa membrane glycoprotein and decreases
intracellular drug concentration by efﬂuxing them from the intracellular
space. Multidrug resistance are known to a major obstacle for suc-
cessful treatment of articular inﬂamation in rheumatoid arthritis (RA)
and can be caused by overexpression of P-gp. Glucocorticoids (GCs),
which is one of the substrates of P-gp, are widely used in the treat-
ment of inﬂammatory joints in Osteoarthritis (OA) and RA with severe
synovitis, when they are uncontrollable with oral medicine or intraar-
ticular injection of hyaluronan. Treatment with GCs is associated with
signiﬁcant dose-dependent side-effects such as obesity, diabetes, im-
mune suppression and osteoporosis. Thereby, it is essential for suc-
cessful treatment of joint inﬂammation that lower dose of GCs ad-
ministration exerts sufﬁcient anti-inﬂammatory effects on arthritic syn-
ovium. In this study, we elucidated that P-gp function in siABCB1b
transfected FLSs was down-regulated and this augmented the anti-
inﬂammatory effect of DEX. These ﬁndings suggest that targeted down-
regulation of ABCB1 gene by siRNA has the potential to reduce ther-
apeutic dosage of GCs in the treatment of inﬂammatory joints in
OA and RA.
Figure 1. ABCB1 gene expression in FLSs. Target mRNA was deter-
mined by real-time PCR. Expression levels of ABCB1a, and ABCB1b
were standardized by ABCB1a mRNA.
Figure 2. Gene silencing effect of siABCB1b (cells not treated with siRNA
as a control).
Figure 3. Inhibitory effects of DEX (at the concentration of 0, 1, 10,
100 nM) on Il-6 mRNA expression in FLS with or without transfection of
siABCB1b.
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Purpose: Bradykinin (BK) is a proinﬂammatory peptide whose effects are
mediated through the activation of B2 receptors expressed by several cell
types. Released BK during inﬂammatory conditions sensitizes sensory
neurons, thus producing pain, and activates cell signalling cascades
thus contributing to the maintenance of inﬂammation. The intra-articular
administration of the peptide B2 receptor antagonist icatibant can reduce
pain in knee osteoarthritis. We have recently presented the pharmaco-
logical proﬁle of MEN16132, a small non-peptide molecule endowed with
high antagonist afﬁnity for the human, guinea pig, and mouse B2 receptor,
which exhibits a long lasting inhibitory effect in preclinical in vivo models.
Aim of the current investigation was to characterize BK B2 receptors
and signalling in human knee synoviocytes (ﬁbroblast-like, HFLS) and
chondrocytes (HCCK) in order to determine the pharmacological proﬁle
of MEN16132 in comparison with icatibant.
Methods: HFLS (ECACC, 408−05a) and HCCK (Lonza, CC-2550) were
cultured according to providers instructions. Experiments were performed
with cells at conﬂuence plated onto 12-well (binding) or 24-well (func-
tional). Radioligand ([3H]BK) binding experiments (incubation time 2h
at 4ºC) were carried out to detect BK afﬁnity (KD) and the number
of binding sites (Bmax), and to evaluate the inhibitory constant afﬁnity
(Ki) of antagonists. Inositolphosphates (IP) accumulation experiments
(incubation time 1h at 37ºC) were performed as index of BK induced
phospholipase C activation and to determine the antagonists potency
(pKB). Data are expressed as mean±s.e.m. of 3 experiments, each in
triplicate.
Results: Saturation data obtained with increasing [3H]BK concentrations
(0.1−30 nM) indicated the presence of BK binding sites both in HFLS and
